Abstract
The transport of 3H-digoxin (an established MDR1 and OATP substrate) was assessed alone, and in the presence of marketed inhaled drug compounds in Calu-3 cell monolayers cultured at an air-liquid interface for 21 days. Net secretory transport of 3H-digoxin was significantly reduced (p<0.01) in the presence of both budesonide and formoterol but not in the presence of salbutamol. Results suggest that therapeutically relevant concentrations of marketed inhaled drugs might interact with drug transporters in the bronchial epithelium
Original language | English |
---|---|
Publication status | Published - 2012 |
Event | UK PharmSci 2012 - Nottingham, United Kingdom Duration: 12 Sept 2012 → 14 Sept 2012 |
Conference
Conference | UK PharmSci 2012 |
---|---|
Country/Territory | United Kingdom |
City | Nottingham |
Period | 12/09/12 → 14/09/12 |